Tumor suppressive microRNA-137 negatively regulates Musashi-1 and colorectal cancer progression
Metrics: PDF 858 views | HTML 675 views | ?
Amber R. Smith1, Rebecca T. Marquez1, Wei-Chung Tsao1, Surajit Pathak3, Alexandria Roy1, Jie Ping3, Bailey Wilkerson1, Lan Lan1, Wenjian Meng3, Kristi L. Neufeld1,4, Xiao-Feng Sun3 and Liang Xu1,2
1 Department of Molecular Biosciences, University of Kansas, Lawrence, KS, USA
2 Department of Radiation Oncology, The Kansas University Medical Center, Kansas City, KS, USA
3 Department of Oncology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
4 Department of Cancer Biology, The Kansas University Medical Center, Kansas City, KS, USA
Liang Xu, email:
Keywords: tumor-initiating cells, microRNAs, RNA-binding proteins, colon cancer, rectal cancer
Received: September 25, 2014 Accepted: March 04, 2015 Published: March, 30, 2015
Stem cell marker, Musashi-1 (MSI1) is over-expressed in many cancer types; however the molecular mechanisms involved in MSI1 over-expression are not well understood. We investigated the microRNA (miRNA) regulation of MSI1 and the implications this regulation plays in colorectal cancer. MicroRNA miR-137 was identified as a MSI1-targeting microRNA by immunoblotting and luciferase reporter assays. MSI1 protein was found to be highly expressed in 79% of primary rectal tumors (n=146), while miR-137 expression was decreased in 84% of the rectal tumor tissues (n=68) compared to paired normal mucosal samples. In addition to reduced MSI1 protein, exogenous expression of miR-137 inhibited cell growth, colony formation, and tumorsphere growth of colon cancer cells. Finally, in vivo studies demonstrated that induction of miR-137 can decrease growth of human colon cancer xenografts. Our results demonstrate that miR-137 acts as a tumor-suppressive miRNA in colorectal cancers and negatively regulates oncogenic MSI1.
Amber R. Smith
Rebecca T. Marquez
Kristi L. Neufeld
Primary Contact _
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.